Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
– Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases – LEHI, Utah, June 16, 2025 /PRNewswire/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining treatment paradigms through inflammation-targeted and resilience-driven therapies, today announced the successful completion of its first-in-human......

